氯吡格雷抵抗的危险因素  

Risk factors for clopidogrel resistance

作　　者：刘艺 陶婷 孙增先[2] Liu Yi;Tao Ting;Sun Zengxian(Xuzhou Medical University Affiliated Lianyungang Hospital,Lianyungang 222006,China;Department of Pharmacy,Lianyungang First People's Hospital,Lianyungang,222006,China)

机构地区：[1]徐州医科大学附属连云港医院,222006 [2]连云港市第一人民医院药学部,222006

出　　处：《国际脑血管病杂志》2021年第7期521-525,共5页International Journal of Cerebrovascular Diseases

摘　　要：氯吡格雷是急性冠状动脉综合征、缺血性卒中以及经皮冠状动脉介入治疗、大血管闭塞性卒中血管内治疗术前和术后最常用的抗血小板药,但其抗血小板效果存在个体差异,即存在氯吡格雷抵抗现象(clopidogrel resistance,CR)。CR通常归因于血浆中巯基代谢物浓度的降低,而引起巯基代谢物浓度降低的因素众多。文章对CR相关危险因素的研究进展进行综述,以便临床医生评估CR风险,采取个体化抗血小板治疗方案,从而改善患者临床转归。Clopidogrel is the most commonly used antiplatelet agent for acute coronary syndrome,ischemic stroke,and before and after percutaneous coronary intervention,and endovascular treatment of large vessel occlusive stroke,but there are individual differences in antiplatelet effect,that is,clopidogrel resistance(CR).CR is usually attributed to the decrease of the concentration of sulfhydryl metabolites in plasma,and there are many factors that cause the decrease of the concentration of sulfhydryl metabolites.This article reviews the research progress of CR-related risk factors,so that clinicians can assess the risk of CR and adopt individualized antiplatelet therapy to improve the clinical outcome of patients.

关 键 词：氯吡格雷 抗药性 危险因素 

分 类 号：R969[医药卫生—药理学]